| First Author | Ohgomori T | Year | 2017 |
| Journal | Neuroscience | Volume | 356 |
| Pages | 114-124 | PubMed ID | 28526579 |
| Mgi Jnum | J:243945 | Mgi Id | MGI:5912724 |
| Doi | 10.1016/j.neuroscience.2017.05.014 | Citation | Ohgomori T, et al. (2017) Differential involvement of vesicular and glial glutamate transporters around spinal alpha-motoneurons in the pathogenesis of SOD1G93A mouse model of amyotrophic lateral sclerosis. Neuroscience 356:114-124 |
| abstractText | From a view point of the glutamate excitotoxicity theory, several studies have suggested that abnormal glutamate homeostasis via dysfunction of glial glutamate transporter-1 (GLT-1) may underlie neurodegeneration in amyotrophic lateral sclerosis (ALS). However, the detailed role of GLT-1 in the pathogenies of ALS remains controversial. To assess this issue, here we elucidated structural alterations associated with dysregulation of glutamate homeostasis using SOD1G93A mice, a genetic model of familial ALS. We first examined the viability of alpha-motoneurons in the lumbar spinal cord of SOD1G93A mice. Measurement of the soma size and density indicated that alpha-motoneurons might be intact at 9weeks of age (presymptomatic stage), then soma shrinkage began at 15weeks of age (progressive stage), and finally neuronal density declined at 21weeks of age (end stage). Next, we carried out the line profile analysis, and found that the coverage of alpha-motoneurons by GLT-1-positive (GLT-1+) astrocytic processes was decreased only at 21weeks of age, while the reduction of coverage of alpha-motoneurons by synaptophysin-positive (SYP+) presynaptic terminals began at 15weeks of age. Interestingly, the coverage of alpha-motoneurons by VGluT2+ presynaptic terminals was transiently increased at 9weeks of age, and then gradually decreased towards 21weeks of age. On the other hand, there were no time-dependent alterations in the coverage of alpha-motoneurons by GABAergic presynaptic terminals. These findings suggest that VGluT2 and GLT-1 may be differentially involved in the pathogenesis of ALS via abnormal glutamate homeostasis at the presymptomatic stage and end stage of disease, respectively. |
